New registry aims to unlock why BRCA mutations lead to pancreatic cancer

NCT ID NCT01983410

Ongoing Knowledge-focused Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study creates a registry for people with BRCA or PALB2 gene mutations who have pancreatic cancer, along with their close relatives. Researchers will collect medical information, blood samples, and tumor tissue to better understand why pancreatic cancer develops in this group. No treatments are tested; the goal is to gather data for future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this registry could help researchers understand why some people with BRCA mutations develop pancreatic cancer, potentially pointing toward better screening or prevention strategies.
What could go wrong: This is an observational registry, not a treatment trial. It collects information and samples but does not test any intervention, so it cannot directly lead to a cure or therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Locations

Abramson Cancer Center at University of Pennsylvania Medical Center

Philadelphia, Pennsylvania, 19104-4283, United States
Cold Springs Harbor Laboratory (Specimen Analysis)

Cold Spring Harbor, New York, 11724, United States
Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Commack

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester

Harrison, New York, 10604, United States
Shaare Zedek Medical Center

Jerusalem, Israel
Sheba Medical Center

Tel Litwinsky, Israel
Weill Cornell Medical College (Specimen Analysis)

New York, New York, United States
Weizmann Institute of Science (Specimen Analysis)

Rehovot, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.